Literature DB >> 16235416

APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 16235416

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Authors:  Monique A Hartley-Brown; Daniel M Sullivan; Rachid Baz
Journal:  Adv Hematol       Date:  2010-06-27

2.  A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

Authors:  Christopher Lieu; Laura Chow; A Scott Pierson; S Gail Eckhardt; Cindy L O'Bryant; Mark Morrow; Zung Vu Tran; John J Wright; Lia Gore
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

3.  Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.

Authors:  Taylor Burkhart; Matthew Cody Lee Keith; Carrie Ann Geisberg Lenneman; Rajeev Ruben Fernando
Journal:  Tex Heart Inst J       Date:  2018-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.